IgG4-RD is characterized by infiltration of the affected organs with IgG4-laden plasma cells, serum IgG4 elevation, typical histopathology and response to corticosteroid therapy.[2] Type 2 AIP is a pancreas-specific disorder not associated with IgG4.[1] Although the AIP subtypes have distinct histologic findings, their clinical distinction www.selleckchem.com/products/LDE225(NVP-LDE225).html is often difficult due to an overlap in presentation, morphologic appearance of the pancreas and variability in serum IgG4 levels.[3] Recently, International Consensus Diagnostic Criteria (ICDC) has been

proposed to provide uniformity to AIP diagnosis.[1] Corticosteroid therapy is generally given to patients who are symptomatic with obstructive jaundice, abdominal pain, constitutional symptoms and extra pancreatic lesions. Peripancreatic vascular lesions Gefitinib ic50 in the setting of acute and chronic pancreatitis have been well recognized. Venous involvement can result in thrombosis or attenuation of the splanchnic veins; in order of decreasing frequency—splenic, superior mesenteric, portal. This causes collaterals to develop in the splenoportal and gastroepiploic systems with resultant complications: upper gastrointestinal bleeding, splenic infarction, and bowel ischemia.[4, 5] In a recent meta-analysis of reported

literature, the prevalence of splenic vein thrombosis in acute or chronic pancreatitis was reported to be 14%.[6] Currently, there are no clear guidelines on the role Resminostat of anticoagulation in splanchnic vein thrombosis resulting from pancreatitis. Arterial involvement (splenic, pancreaticoduodenal, gastroduodenal, left gastric) can result in direct erosion of the vessel wall or development of pseudoaneurysms; hemorrhage is the primary complication.[4, 5] The pathogenesis of vascular involvement in pancreatitis is believed to be due to local factors

rather than a pre-existing hypercoagulable state. In a recent study that systematically evaluated patients with recurrent acute and chronic alcoholic pancreatitis, the prevalence of hypercoagulable factors was similar among patients who did and did not have extrahepatic portal venous system thrombosis.[7] Inflammatory changes and release of proteolytic enzymes in the pancreas/peripancreatic area, or complications such as necrosis and pancreatic/peripancreatic fluid collections, lead to inflammatory changes in the vessel wall, stasis of blood circulation and weakening of the vessel wall. Compression of the vessels can also result from fibrotic changes in chronic pancreatitis.[4, 5] Data on peripancreatic vascular involvement in patients with AIP is limited, and confined to Type 1 AIP.[8-10] Kamisawa et al. evaluated 14 AIP patients with abdominal angiography and found marked stenosis of the portal vein in four and encasement of the peripancreatic arteries in eight patients.